Morphine Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population

Athena F Zuppa1,2, Giselle R Benitez3, Nicole R Zane2

  • 1Department of Pediatric Anesthesia and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.

Critical Care Medicine
|March 29, 2019
PubMed

Insights

This study modeled morphine pharmacokinetics in critically ill children, finding weight and age predict drug levels. Prolonged ventilation impacts morphine metabolism, but genetic factors were not identified in this cohort.

Area of Science:

  • Pharmacology
  • Pediatric Critical Care
  • Pharmacogenomics

Background:

  • Critically ill children require precise medication dosing.
  • Morphine is commonly used for pain and sedation in pediatric intensive care units (PICUs).
  • Understanding morphine's disposition is crucial for optimizing therapy in vulnerable pediatric populations.

Purpose of the Study:

  • To develop a pharmacokinetic-pharmacogenomic population model for morphine in critically ill children.
  • To identify factors influencing morphine and its metabolite concentrations.
  • To explore potential genetic influences on morphine metabolism.

Main Methods:

  • Prospective observational study in 13 US PICUs.
  • Included 66 mechanically ventilated pediatric patients receiving morphine infusions.
  • Utilized serial blood sampling for drug/metabolite quantification and genotyping; analyzed using nonlinear mixed-effects modeling.

Main Results:

  • Body weight and postmenstrual age were significant predictors of morphine and metabolite pharmacokinetics.
  • Mechanical ventilation duration >= 10 days reduced metabolite formation/elimination by over 30%.
  • No heritable factors (e.g., UGT2B7) were identified due to sample size and population heterogeneity.

Conclusions:

  • Established a pharmacokinetic model for morphine in critically ill children, highlighting nonheritable factors.
  • Provides a foundation for future research into genetic influences on morphine metabolism.
  • Emphasizes the impact of ventilation duration on morphine disposition in pediatric patients.
Abstract

Related Concept Videos

Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
951
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
488
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
220
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
857
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
278